Stocks · News reference
UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19
UBS analyst Patrick Wood initiates coverage on Integra Lifesciences (NASDAQ:IART) with a Neutral rating and announces Price Target of $19.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 28, 2026, 6:21 PM
- Checked
- Jul 28, 2026, 6:21 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18
Read original at benzingaIntegra LifeSciences shares are trading lower. The company reported Q2 financial results and lowered its FY26 sales guidance.
Read original at benzinga8-K filing — INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
Filed: 2026-07-29 AccNo: 0000917520-26-000055 Size: 427 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar